- Home
- RLTY vs AQST Comparison
RLTY vs AQST Comparison
Compare RLTY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- AQST
- Stock Information
- Founded
- RLTY 2022
- AQST 2004
- Country
- RLTY United States
- AQST United States
- Employees
- RLTY N/A
- AQST N/A
- Industry
- RLTY Investment Managers
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- AQST Health Care
- Exchange
- RLTY Nasdaq
- AQST Nasdaq
- Market Cap
- RLTY 259.2M
- AQST 285.4M
- IPO Year
- RLTY N/A
- AQST 2018
- Fundamental
- Price
- RLTY $15.71
- AQST $3.01
- Analyst Decision
- RLTY
- AQST Strong Buy
- Analyst Count
- RLTY 0
- AQST 8
- Target Price
- RLTY N/A
- AQST $10.38
- AVG Volume (30 Days)
- RLTY 86.7K
- AQST 2.0M
- Earning Date
- RLTY 01-01-0001
- AQST 03-05-2025
- Dividend Yield
- RLTY 9.35%
- AQST N/A
- EPS Growth
- RLTY N/A
- AQST N/A
- EPS
- RLTY N/A
- AQST N/A
- Revenue
- RLTY N/A
- AQST $58,900,000.00
- Revenue This Year
- RLTY N/A
- AQST $18.44
- Revenue Next Year
- RLTY N/A
- AQST N/A
- P/E Ratio
- RLTY N/A
- AQST N/A
- Revenue Growth
- RLTY N/A
- AQST 22.56
- 52 Week Low
- RLTY $11.38
- AQST $2.24
- 52 Week High
- RLTY $14.60
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- RLTY 58.43
- AQST 43.29
- Support Level
- RLTY $15.35
- AQST $2.95
- Resistance Level
- RLTY $15.67
- AQST $3.21
- Average True Range (ATR)
- RLTY 0.24
- AQST 0.20
- MACD
- RLTY -0.01
- AQST 0.02
- Stochastic Oscillator
- RLTY 81.36
- AQST 18.42
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.